| ID | 1359 |
| Name of the vaccine | Infanrix+Hib |
| Microbe | Bacteria |
| Disease name | Haemophilus influenzae type b (Hib) |
| Name of bacteria | Haemophilus influenzae |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 18 to 24 months |
| Description of the vaccine | DTPa/Hib vaccine. |
| Name of the manufacturer | GlaxoSmithKline |
| Name of the manufacturing country | China |
| Year of manufacture | 2012 |
| Clinical Phase status | Clinical - Phase 3 |
| Bacterial strain | Anaerobic gram-negative coccobacillus. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Single booster dose in children with 3 doses of the Infanrix-IPV/Hib. |
| Mechanism of action | Anti-polyribosyl-ribitol-phosphate (PRP) antibody. |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For acellular pertussis, tetanus and diphtheria. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | 18251697 |
| Clinical trial number | NCT01449812 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|